Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexandra Dubinskaya

Urogynecology and Reconstructive Pelvic Surgery Beverly Hills, CA Medical Doctor

NPI 1356799340 CMS profile 2444787

99 N La Cienega Blvd # 202M102, Ste M102, Beverly Hills, CA 90211

Open in the dashboard

General payments

$15,739

106 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandra Dubinskaya of Beverly Hills, CA is reported in the CMS Open Payments database as having received $15,739 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $358 10
2024 General $1,088 19
2023 General $2,293 27
2022 General $1,071 27
2021 General $10,774 21
2020 General $19 1
2019 General $136 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandra Dubinskaya
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Alexandra Dubinskaya were reported at $358. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Alexandra Dubinskaya Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $136 $799 $319–$2,013 $163
2020 $19 $384 $158–$1,360 $114
2021 $10,774 $641 $247–$2,515 $132
2022 $1,071 $843 $347–$2,794 $149
2023 $2,293 $819 $308–$2,302 $160
2024 $1,088 $882 $306–$2,459 $164
2025 $358 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $13,283 78 payments
  2. Intuitive Surgical, Inc. $1,029 2 payments
  3. Boston Scientific Corporation $741 9 payments
  4. Coloplast Corp $169 5 payments
  5. Astellas Pharma Global Development $162 2 payments
  6. Allergan Inc. $136 1 payment
  7. AbbVie, Inc. $101 5 payments
  8. Ambu Inc. $42 1 payment
  9. Bluewind Medical $29 1 payment
  10. Teleflex LLC $27 1 payment
  11. Other $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $10,000 1 payment
  2. Food and Beverage $4,739 104 payments
  3. Education $1,000 1 payment
Products named General payments · program years 2019–2025
  1. INTERSTIM $13,253 76 payments
  2. DAVINCI XI $1,000 1 payment
  3. Solyx SIS System $457 4 payments
  4. MYRBETRIQ $162 2 payments
  5. AdVance XP $154 2 payments
  6. BOTOX Urology $136 1 payment
  7. Altis $95 2 payments
  8. BOTOX Botox Therapeutic $86 4 payments
  9. LigaSure $31 2 payments
  10. Da Vinci Surgical System $29 1 payment
  11. Other $134 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

212

Median for Obstetrics & Gynecology: 65

Drug cost

$33,686

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

22.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 23 $21,945
Estradiol Generic 87 $7,123
Methenamine Hippurate Generic 39 $2,666
Yuvafem Estradiol Brand 11 $1,709
Fluconazole Generic 12 $89
Cephalexin Generic 15 $63
Oxycodone Hcl Generic 11 $47
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 14 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$49,112

Medicare's payments for the services billed

Medicare patients

129

Average age 74

Services billed

858

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Osteoporosis 34%
Ischemic heart disease 31%
Depression 24%
Diabetes 23%
Cancer 19%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record